Quick answers
- What is Desoximetasone used for?
- The FDA-approved label (Topicort, Sun Pharmaceutical Industries, Inc., March 12, 2026) says: “Topicort ® (desoximetasone ointment USP) 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Desoximetasone have a boxed warning?
- No. None of the 33 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Desoximetasone?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Desoximetasone been recalled?
- FDA enforcement reports list 3 recalls of products of this medicine; the newest started September 13, 2016 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Desoximetasone?
- 12 companies list prescription products of Desoximetasone in the FDA NDC Directory, including Sun Pharmaceutical Industries, Inc., Bryant Ranch Prepack and Lupin Pharmaceuticals, Inc..
What Desoximetasone is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Topicort ® (desoximetasone ointment USP) 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
— FDA label: Topicort, Sun Pharmaceutical Industries, Inc., effective March 12, 2026. Read the full label on DailyMed →
The FDA has 33 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 33 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Ointment · Cream · Spray · Gel |
|---|---|
| Route | Topical |
| Prescription products | 36 in the FDA NDC Directory |
| Brand names | Topicort |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| desoximetasone 0.05% cream | Generic | $1.51 per gram |
| desoximetasone 0.05% gel | Generic | $3.19–$3.75 per gram 2 packages, lowest to highest |
| desoximetasone 0.05% ointment | Generic | $1.15 per gram |
| desoximetasone 0.25% cream | Generic | $0.3098–$0.4700 per gram 10 packages, lowest to highest |
| desoximetasone 0.25% ointment | Generic | $0.2264–$1.09 per gram 9 packages, lowest to highest |
| desoximetasone 2.5 mg/mL spray | Generic | $0.6955 per mL |
NADAC list of November 4, 2026; these prices took effect between August 19, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Sun Pharmaceutical Industries, Inc.8 products
- Bryant Ranch Prepack7 products
- Lupin Pharmaceuticals, Inc.5 products
- Padagis Israel Pharmaceuticals Ltd3 products
- Proficient Rx LP2 products
- Saptalis Pharmaceuticals, LLC.2 products
- Zydus Lifesciences Limited2 products
- A-S Medication Solutions2 products
- Viona Pharmaceuticals Inc2 products
- Actavis Pharma, Inc.1 product
- Novel Laboratories, Inc.1 product
- The J. Molner Company LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA018594 TOPICORT | Taro | January 17, 1985 | 10, latest November 6, 2015 2015: Manufacturing (CMC) · 2014: Manufacturing (CMC) · 2014: Manufacturing (CMC) |
| NDA204141 TOPICORT | Sun Pharma Canada | April 11, 2013 | 5, latest October 7, 2021 2021: Efficacy · 2015: Labeling · 2015: Manufacturing (CMC) |
Generic approvals (20)
- ANDA073193Taro · November 29, 1990
- ANDA073210Taro · November 30, 1990
- ANDA074286Taro · June 7, 1996
- ANDA074904Taro · July 14, 1998
- ANDA076510Padagis Israel · July 1, 2003
- ANDA077770Padagis Israel · April 20, 2015
- ANDA203234Sciegen Pharms · June 12, 2015
- ANDA205082Actavis Mid Atlantic · September 4, 2015
- ANDA206792Novel Labs Inc · May 10, 2016
- ANDA204965Actavis Mid Atlantic · November 7, 2016
- ANDA208104Lupin · December 1, 2016
- ANDA208044Lupin · December 12, 2016
- ANDA203787Sciegen Pharms · January 6, 2017
- ANDA208164Lupin · January 9, 2017
- ANDA208163Lupin · January 11, 2017
- ANDA206441Padagis Israel · January 20, 2017
- ANDA205206Zydus Lifesciences · September 19, 2017
- ANDA208124Lupin · March 16, 2018
- ANDA205620Zydus Lifesciences · September 28, 2018
- ANDA209973The J Molner · October 23, 2018
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
September 13, 2016 · Class II · Terminated · D-0116-2017
Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).
Desoximetasone Cream USP, 0.25% 100 g, Rx only, mfd. by Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532; NDC 51672-1270-7 — Taro Pharmaceuticals, Inc.
-
September 13, 2016 · Class II · Terminated · D-0117-2017
Failed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).
Desoximetasone Cream USP, 0.05% 100 g, Rx only, mfd. by Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1, Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532; NDC 51672-1271-7 — Taro Pharmaceuticals, Inc.
-
August 5, 2015 · Class III · Terminated · D-1370-2015
Failed Impurities/Degradation Specifications: Out of specification results for impurities testing was obtained at the 6 and 9 month time points.
Topicort (desoximetasone) Topical Spray, 0.25%, 100 mL Bottles, Rx Only. Mfd by: Taro Pharmaceuticals, Inc., Brampton, Ontario, Canada, L6T 1C1, Dist by: TaroPharma, Hawthorne, NY 10532. NDC: 51672-5281-7. — Taro Pharmaceuticals, Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Topicort, Sun Pharmaceutical Industries, Inc., effective March 12, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →